Mirador Therapeutics emerged from stealth Thursday with financing from ARCH Venture Partners and Sanofi, among others, to provide precision medicines for inflammatory and fibrotic diseases.
Pictured: 3d illustration of antibodies attacking virus cell in the bloodstream iStock/Christoph Burgstedt
Mirador Therapeutics, a precision medicine startup, launched with $400 million in financing Thursday as it looks to advance multiple therapeutic programs targeting immune-mediated inflammatory and fibrotic diseases.
The San Diego-based biotech’s funding was led by ARCH Venture Partners, including early investments from OrbiMed and Fairmount. Other investors included Fidelity Management & Research Company, Sanofi Ventures, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Wooldine Partners LP, Alexandria Venture Investments, RTW Investments and Venrock Healthcare Capital Partners.
The company was founded by Mark McKenna, who is also the CEO of Mirador. McKenna is the former CEO of Prometheus Biosciences, acquired by Merck last year for $10.8 billion. Other alums include Olivier Laurent, former chief science officer and head of R&D at Prometheus, who will serve as Mirador’s CSO. Former Prometheus CMO Allison Luo will serve as Mirador’s CMO.
Mirador plans to use its development engine, known as Mirador360, which will leverage a combination of human genetics and data science to create first-in-class or best-in-class precision medicines. The Mirador360 platform is meant to “harmonize” millions of patient molecular profiles to find genetic associations to immune-fibrotic diseases and new therapeutic targets.
“At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy,” McKenna said in a statement. “The industry has only scratched the surface of utilizing advances in human genetics—coupled with exponential progress in machine learning—to accelerate the development of precision therapies for patients who need them the most. With a proven team, distinguished board of directors, leading healthcare investors, and proprietary data-driven approach, we aim to create a leading precision medicine company of a scale that provides important new treatment options for patients.”
Thursday’s announcement did not provide details on the therapy targets or when they are anticipated to go to the clinic.
Mirador joins several other biotechs who have recently emerged on the scene. Wednesday, T cell engager biotech Clasp Therapeutics launched with $150 million in financing. Kenai Therapeutics also launched late last month with $82 Million and an asset to treat Parkinson’s disease.
Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.
